AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy
Joan Anton Puig‐Butillé(Hospital Clínic de Barcelona), Àngels Fabra(Duran i Reynals Hospital), Josep M. Piulats(Institut Català d'Ornitologia), Eduard Cabré, Paula Aguilera(Centre for Biomedical Network Research on Rare Diseases), Gemma Tell‐Martí(Centre for Biomedical Network Research on Rare Diseases), Luís Palomero(Institut d'Investigació Biomédica de Bellvitge), Antònia Vinyals(Institut d'Investigació Biomédica de Bellvitge), Célia Bádenas(Centre for Biomedical Network Research on Rare Diseases), Joaquim Marcoval(Bellvitge University Hospital), Francesca Mateo(Institut d'Investigació Biomédica de Bellvitge), J.R. Ferreres(Bellvitge University Hospital), Susana Puig(Instituto de Salud Carlos III), Josep Malvehy(Universitat de Barcelona), Miguel Ángel Pujana(Bellvitge University Hospital)
Cited by 60
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634